Acute coronary syndrome percutaneous coronary intervention(PCI)postoperative platelet type Ⅱ secondary thrombocytopenia to analysis the clinical effect of fondaparinux
10.3969/j.issn.1005-1678.2017.06.010
- VernacularTitle:急性冠脉综合征经皮冠状动脉介入治疗术后继发Ⅱ型血小板减少症给予磺达肝癸钠的临床综合效果分析
- Author:
Wanglan XU
;
Pei LIU
;
Xiaoying YAO
;
Baizhi PI
;
Juanjuan XUAN
;
Jun YAO
- Keywords:
acute coronary syndrome;
PCI;
HIT-Ⅱ
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(6):35-37
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effects of acute coronary comprehensive syndrome with PCI therapy after secondary HIT-Ⅱ give sulphur of liver fondaparinux therapy clinical comprehensive effect.MethodsDecimation in 66 patients with acute coronary syndrome after PCI patients was applied on the basis of drug therapy and postoperative anticoagulation.Study group (33 cases) in the postoperative secondary HIT Ⅱ after being diagnosed with stop heparin and give sulphur of fondaparinux, bleeding in the coagulation indexes, within 30 days event and 6months heart vascular pieces efficacy evaluation.ResultsThe use of heparin before.The index of blood coagulation in study group were normal, confirmed HIT Ⅱ when the index change significantly (P<0.05) and the discontinuation of heparin 24h, 3d, 7d indexes compared at diagnosis were restored (P<0.05) and 14 days of heparin to stop with the use of heparin levels.The patients in the study group, the incidence of bleeding events was 9.1%, compared to 15.2% in the control group no significant difference.The patients in the study group of adverse cardiovascular events occurred rate was 12.1%, compared to 18.2% in the control group no significant difference.ConclusionAcute coronary syndrome after PCI HIT-Ⅱ to grant the sulphur of fondaparinux treatment had no significant effect on blood coagulation function and safety.
